Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a condition affecting both eyes called retinitis pigmentosa, or another inherited retinal condition that damages side (peripheral) vision, confirmed by past eye examination records
- People whose best vision (with glasses or contact lenses if needed) in at least one eye falls within a certain range of significant vision loss (confirm with trial site for exact measurements)
- People who can communicate reasonably well in English or Spanish
Who may not be able to join:
- People whose memory loss, dementia, or cognitive difficulties are severe enough that they cannot fully understand and agree to take part, or that would make completing the study tasks too difficult, in the opinion of the study doctor
- People whose personal circumstances, in the opinion of the study doctor, would make it difficult to take part in or follow the study requirements
- People who are currently pregnant, as reported by the patient
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 949-264-3793
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Operational feasibility of testing moderate to profound vision impaired patients with various retinal dystrophies on a battery of visual assessments
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.